4//SEC Filing
Sachs David C. 4
Accession 0001326110-25-000022
CIK 0001326110other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 9:11 PM ET
Size
9.3 KB
Accession
0001326110-25-000022
Insider Transaction Report
Form 4
Sachs David C.
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2025-02-22$3.42/sh−15,860$54,241→ 225,620 total - Exercise/Conversion
Common Stock
2025-02-22+40,650→ 241,480 total - Exercise/Conversion
Restricted Stock Units
2025-02-22−40,650→ 81,301 total→ Common Stock (40,650 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
- [F2]On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld.
- [F3]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
Documents
Issuer
ImmunityBio, Inc.
CIK 0001326110
Entity typeother
Related Parties
1- filerCIK 0001848899
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 9:11 PM ET
- Size
- 9.3 KB